KNSA vs. UTHR: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at KNSA and UTHR, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
| Symbol | KNSA | UTHR |
|---|---|---|
| Company Name | Kiniksa Pharmaceuticals International, plc | United Therapeutics Corporation |
| Country | United Kingdom | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Biotechnology | Biotechnology |
| Market Capitalization | 2.49 billion USD | 14.01 billion USD |
| Exchange | NasdaqGS | NasdaqGS |
| Listing Date | May 25, 2018 | June 17, 1999 |
| Security Type | Common Stock | Common Stock |
Historical Performance
This chart compares the performance of KNSA and UTHR by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | KNSA | UTHR |
|---|---|---|
| 5-Day Price Return | 0.18% | 3.44% |
| 13-Week Price Return | 25.93% | -0.35% |
| 26-Week Price Return | 66.99% | -12.45% |
| 52-Week Price Return | 30.23% | -7.21% |
| Month-to-Date Return | 8.33% | 12.75% |
| Year-to-Date Return | 65.72% | -12.22% |
| 10-Day Avg. Volume | 0.78M | 0.89M |
| 3-Month Avg. Volume | 0.77M | 0.57M |
| 3-Month Volatility | 45.25% | 40.95% |
| Beta | 0.15 | 0.62 |
Profitability
Return on Equity (TTM)
KNSA
1.05%
Biotechnology Industry
- Max
- 77.14%
- Q3
- 10.76%
- Median
- -20.08%
- Q1
- -42.71%
- Min
- -119.20%
KNSA’s Return on Equity of 1.05% is on par with the norm for the Biotechnology industry, indicating its profitability relative to shareholder equity is typical for the sector.
UTHR
18.73%
Biotechnology Industry
- Max
- 77.14%
- Q3
- 10.76%
- Median
- -20.08%
- Q1
- -42.71%
- Min
- -119.20%
In the upper quartile for the Biotechnology industry, UTHR’s Return on Equity of 18.73% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
Net Profit Margin (TTM)
KNSA
0.90%
Biotechnology Industry
- Max
- 59.44%
- Q3
- 16.21%
- Median
- -11.49%
- Q1
- -167.42%
- Min
- -409.07%
KNSA’s Net Profit Margin of 0.90% is aligned with the median group of its peers in the Biotechnology industry. This indicates its ability to convert revenue into profit is typical for the sector.
UTHR
40.36%
Biotechnology Industry
- Max
- 59.44%
- Q3
- 16.21%
- Median
- -11.49%
- Q1
- -167.42%
- Min
- -409.07%
A Net Profit Margin of 40.36% places UTHR in the upper quartile for the Biotechnology industry, signifying strong profitability and more effective cost management than most of its peers.
Operating Profit Margin (TTM)
KNSA
0.85%
Biotechnology Industry
- Max
- 60.62%
- Q3
- 20.76%
- Median
- -12.41%
- Q1
- -181.14%
- Min
- -482.02%
KNSA’s Operating Profit Margin of 0.85% is around the midpoint for the Biotechnology industry, indicating that its efficiency in managing core business operations is typical for the sector.
UTHR
47.05%
Biotechnology Industry
- Max
- 60.62%
- Q3
- 20.76%
- Median
- -12.41%
- Q1
- -181.14%
- Min
- -482.02%
An Operating Profit Margin of 47.05% places UTHR in the upper quartile for the Biotechnology industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
Profitability at a Glance
| Symbol | KNSA | UTHR |
|---|---|---|
| Return on Equity (TTM) | 1.05% | 18.73% |
| Return on Assets (TTM) | 0.80% | 16.48% |
| Net Profit Margin (TTM) | 0.90% | 40.36% |
| Operating Profit Margin (TTM) | 0.85% | 47.05% |
| Gross Profit Margin (TTM) | 85.93% | 88.98% |
Financial Strength
Current Ratio (MRQ)
KNSA
3.57
Biotechnology Industry
- Max
- 19.31
- Q3
- 9.38
- Median
- 4.54
- Q1
- 2.45
- Min
- 0.76
KNSA’s Current Ratio of 3.57 aligns with the median group of the Biotechnology industry, indicating that its short-term liquidity is in line with its sector peers.
UTHR
7.26
Biotechnology Industry
- Max
- 19.31
- Q3
- 9.38
- Median
- 4.54
- Q1
- 2.45
- Min
- 0.76
UTHR’s Current Ratio of 7.26 aligns with the median group of the Biotechnology industry, indicating that its short-term liquidity is in line with its sector peers.
Debt-to-Equity Ratio (MRQ)
KNSA
0.00
Biotechnology Industry
- Max
- 1.35
- Q3
- 0.64
- Median
- 0.09
- Q1
- 0.00
- Min
- 0.00
KNSA’s Debt-to-Equity Ratio of 0.00 is typical for the Biotechnology industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
UTHR
0.00
Biotechnology Industry
- Max
- 1.35
- Q3
- 0.64
- Median
- 0.09
- Q1
- 0.00
- Min
- 0.00
UTHR’s Debt-to-Equity Ratio of 0.00 is typical for the Biotechnology industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
Interest Coverage Ratio (TTM)
KNSA
--
Biotechnology Industry
- Max
- 72.37
- Q3
- 1.91
- Median
- -7.81
- Q1
- -63.90
- Min
- -153.80
Interest Coverage Ratio data for KNSA is currently unavailable.
UTHR
42.15
Biotechnology Industry
- Max
- 72.37
- Q3
- 1.91
- Median
- -7.81
- Q1
- -63.90
- Min
- -153.80
UTHR’s Interest Coverage Ratio of 42.15 is in the upper quartile for the Biotechnology industry, signifying a strong and healthy capacity to meet its interest payments from operating profits.
Financial Strength at a Glance
| Symbol | KNSA | UTHR |
|---|---|---|
| Current Ratio (MRQ) | 3.57 | 7.26 |
| Quick Ratio (MRQ) | 2.88 | 6.94 |
| Debt-to-Equity Ratio (MRQ) | 0.00 | 0.00 |
| Interest Coverage Ratio (TTM) | -- | 42.15 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
KNSA
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
KNSA currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
UTHR
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
UTHR currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
Dividend Payout Ratio (TTM)
KNSA
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
KNSA has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
UTHR
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
UTHR has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
Dividend at a Glance
| Symbol | KNSA | UTHR |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
Price-to-Earnings Ratio (TTM)
KNSA
520.61
Biotechnology Industry
- Max
- 60.14
- Q3
- 38.17
- Median
- 29.01
- Q1
- 15.12
- Min
- 0.00
At 520.61, KNSA’s P/E Ratio is exceptionally high, exceeding the typical maximum for the Biotechnology industry. This suggests the stock may be significantly overvalued compared to its peers and implies high market expectations that could be difficult to meet.
UTHR
11.06
Biotechnology Industry
- Max
- 60.14
- Q3
- 38.17
- Median
- 29.01
- Q1
- 15.12
- Min
- 0.00
In the lower quartile for the Biotechnology industry, UTHR’s P/E Ratio of 11.06 suggests the stock may be undervalued compared to its peers, potentially presenting an attractive entry point for investors.
Price-to-Sales Ratio (TTM)
KNSA
4.71
Biotechnology Industry
- Max
- 76.98
- Q3
- 36.53
- Median
- 9.49
- Q1
- 4.49
- Min
- 0.00
KNSA’s P/S Ratio of 4.71 aligns with the market consensus for the Biotechnology industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
UTHR
4.47
Biotechnology Industry
- Max
- 76.98
- Q3
- 36.53
- Median
- 9.49
- Q1
- 4.49
- Min
- 0.00
In the lower quartile for the Biotechnology industry, UTHR’s P/S Ratio of 4.47 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.
Price-to-Book Ratio (MRQ)
KNSA
4.08
Biotechnology Industry
- Max
- 20.53
- Q3
- 9.76
- Median
- 4.77
- Q1
- 2.49
- Min
- 0.59
KNSA’s P/B Ratio of 4.08 is within the conventional range for the Biotechnology industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
UTHR
1.81
Biotechnology Industry
- Max
- 20.53
- Q3
- 9.76
- Median
- 4.77
- Q1
- 2.49
- Min
- 0.59
UTHR’s P/B Ratio of 1.81 is in the lower quartile for the Biotechnology industry. From a value investing perspective, this is favorable, as it suggests the stock is trading at a discount to its net asset value and may offer a greater margin of safety.
Valuation at a Glance
| Symbol | KNSA | UTHR |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 520.61 | 11.06 |
| Price-to-Sales Ratio (TTM) | 4.71 | 4.47 |
| Price-to-Book Ratio (MRQ) | 4.08 | 1.81 |
| Price-to-Free Cash Flow Ratio (TTM) | 36.28 | 12.83 |